TITAN PHARMACEUTICAL (TTP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (40)	1/26/1999 1:26:00 PM
From: scaram(o)uche	Read Replies (1) of 362

I still find it helpful, looking at the market cap for CLPA, to think of piv in these terms..... biotechclinician.com biotechclinician.com >> works by inhibiting a cyclic GMP (cGMP) phosphodiesterase (PDE) and inducing selective apoptosis << >> The selective apoptotic pathway works via a novel cGMP-PDE that is an enzyme that degrades a secondary messenger (the cGMP). In apoptosis, cGMP increases and activates protein kinase G that decreases cyclic AMP (cAMP) inducing apoptosis. In neoplastic cells the cGMP-PDE is present, which breaks down the cGMP, not allowing the increase needed to induce apoptosis. Prevatac (exisulind) inhibits the cGMP-PDE, allowing apoptosis. The company believes this specific subtype of cGMP-PDE is present in a number of neoplastic cell lines but not normal cells. <<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next